Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares continue to fall Wednesday after news Tuesday that the FDA issued a Complete Response Letter (CRL) for aflibercept 8 mg Biologics License application due to an ongoing review of inspection findings at a third-party filler. Several analysts also lowered their price targets on the stock.
What To Know: The issuance of the CRL effectively denied the company approval of a higher-dose version of EYLEA.
- Canaccord Genuity analyst John Newman downgraded Regeneron Pharmaceuticals from Buy to Hold and lowered the price target from $953 to $720.
- Barclays analyst Carter Gould maintained Regeneron Pharmaceuticals with a Overweight and lowered the price target from $915 to $888.
- RBC Capital analyst Brian Abrahams maintained Regeneron Pharmaceuticals with a Sector Perform and lowered the price target from $816 to $789.
- Baird analyst Brian Skorney maintained Regeneron Pharmaceuticals with a Neutral and lowered the price target from $800 to $760.
- Truist Securities analyst Robyn Karnauskas maintained Regeneron Pharmaceuticals with a Buy and lowered the price target from $1050 to $1045.
Related Link: Google Accused of Breaching Promised Ad Standards, Big Brands and Government Agencies Affected
REGN Price Action: Shares of REGN were down 2.38% at $699.04 at the time of publication, according to Benzinga Pro.
Image by Pexels from Pixabay
